Eledon Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary
14/05/2025 21:17
Eledon Pharmaceuticals Inc ELDN.OQ reported a quarterly adjusted loss of 8 cents per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -34 cents. The mean expectation of three analysts for the quarter was for a loss of 30 cents per share. Wall Street expected results to range from -32 cents to -28 cents per share. Reported revenue was zero; analysts expected zero. Eledon Pharmaceuticals Inc's reported EPS for the quarter was a loss of 8 cents. The company reported a quarterly loss of $6.5 million. Eledon Pharmaceuticals Inc shares had fallen by 14.5% this quarter and lost 29.6% so far this year. FORECAST CHANGES The mean earnings estimate of analysts had fallen by about 19.7% in the last three months. In the last 30 days, there have been no earnings estimate revisions by analysts covering the company. RECOMMENDATIONS The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." Wall Street's median 12-month price target for Eledon Pharmaceuticals Inc is $9.00 This summary was machine generated from LSEG data May 14 at 08:17 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Mar. 31 2025 | -0.30 | -0.08 | Beat |
| Dec. 31 2024 | -0.32 | 0.67 | Beat |
| Sep. 30 2024 | -0.31 | -0.32 | Missed |
| Jun. 30 2024 | -0.30 | -1.06 | Missed |
Recent news on Eledon Pharmaceuticals
See all newsBrief: Eledon Presents Updated Long-Term Phase 2 Bestow Extension Study Results At The International Congress Of The Transplantation Society
Eledon Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Eledon Pharmaceuticals Q2 net loss widens on warrant liability changes
Eledon Pharmaceuticals Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Natera And Eledon Announce Strategic Partnership For Prospera™ Monitoring In Planned Phase 3 Kidney Transplant Trial